| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC3462 |
| Trial ID | NCT05881525 |
| Disease | Advanced Solid Tumor |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| Co-treatment | Nab-paclitaxel |
| HLA | HLA-A2 (except HLA-A*0203) |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase I/II Clinical Study of TC-N201 Injection for the Treatment of Advanced Solid Tumors With HLA-A2 Expression and Positive NY-ESO-1. |
| Year | 2023 |
| Country | China |
| Company sponsor | TCRCure Biopharma Ltd. |
| Other ID(s) | TC-N201-ST |
| Cohort 1 | |||||||||
|
|||||||||